AAD  Vol.6 No.1 , March 2017
Cyclic E2 and P4 on Alzheimer’s Disease Pathways
Abstract: In recent years, Alzheimer’s disease has been clearly linked to the degradation of microtubules and microtubule-associated tau (τ) and β-amyloid (βA) proteins. Through an examination and evaluation of current literature, we assess the possible effects of the steroid hormones on τ hyperphosphorylation and the regulation of βA proteins and their influence on Alzheimer’s dementia and memory loss. We present a mechanism by which Alzheimer’s cases may be reduced or perhaps even prevented through the use of non-synthetic, steroid hormones prescribed in a cyclic dosing schedule that mimics the rhythmic, escalating and descending production normally observed in a reproductive female body. Given the ability of estrogen to prevent τ hyperphosphorylation and increase metabolism of the βA precursor protein, we propose the possibility of controlling both protein cycles through the exogenous application of estrogen and progesterone may help those patients with active disease as well as prevent the onset of Alzheimer’s and other neurodegenerative diseases.
Cite this paper: S. Wiley, T. and Haraldsen, J. (2017) Cyclic E2 and P4 on Alzheimer’s Disease Pathways. Advances in Alzheimer's Disease, 6, 32-44. doi: 10.4236/aad.2017.61003.

[1]   Ouslander, J.G., Studenski, S. and Halter, J.B. (2009) Hazzard’s Geriatric Medicine and Gerontology. 6th Edition, The McGraw-Hill Companies, New York.

[2]   Katzman, R. and Saitoh, T. (1991) Advances in Alzheimer’s Disease. The FASEB Journal, 5, 278.

[3]   Mann, D.M. and Esiri, M.M. (1989) The Pattern of Acquisition of Plaques and Tangles in the Brains of Patients under 50 Years of Age with Down’s Syndrome. Journal of the Neurological Sciences, 89, 169-179.

[4]   Selkoe, D.J. (1991) The Molecular Pathology of Alzheimer’s Disease. Neuron, 6, 487.

[5]   Blessed, G., Tomlinson, B.E. and Roth, M. (1968) The Association between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects. The British Journal of Psychiatry, 114, 797.

[6]   Armstrong, R. (2013) What Causes Alzheimer’s Disease? Folia Neuropathologica, 5, 169-188.

[7]   Bhat, A.H., Dar, K.B., Anees, S., Zargar, M.A., Masood, A., Sofi, M.A., et al. (2015) Review: Oxidative Stress, Mitochondrial Dysfunction and Neurodegenerative Diseases: A Mechanistic Insight. Biomedicine & Pharmacotherapy, 74, 101-110.

[8]   Castellani, R., Hirai, K., Aliev, G., Drew, K.L., Nunomura, A., Takeda, A., et al. (2002) Role of Mitochondrial Dysfunction in Alzheimer’s Disease. Journal of Neuroscience Research, 70, 357-360.

[9]   Maccioni, R.B., Muñoz, J.P. and Barbeito, L. (2001) The Molecular Bases of Alzheimer’s Disease and other Neurodegenerative Disorders. Archives of Medical Research, 32, 367-381.

[10]   Shin, R.W., Iwaki, T., Kitamoto, T. and Tateishi, J. (1991) Hydrated Autoclave Pretreatment Enhances Tau Immunoreactivity in Formalin-Fixed Normal and Alzheimer’s Disease Brain Tissues. Laboratory Investigation, 64, 693-702.

[11]   Lei, P., Ayton, S., Finkelstein, D.I., Adlard, P.A., Masters, C.L. and Bush, A.I. (2010). Tau Protein: Relevance to Parkinson’s Disease. The International Journal of Biochemistry & Cell Biology, 42, 1775-1778.

[12]   Brier, M.R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N.J., Holtzman, D.M., Fagan, A.M., Morris, J.C., Benzinger, T.L.S. and Ances, B.M. (2016) Tau and Ab Imaging, CSF Measures, and Cognition in Alzheimer’s Disease. Science Translational Medicine, 8, 338.

[13]   Weingarten, M.D., Lockwood, A.H., Hwo, S.Y. and Kirschner, M.W. (1975) A Protein Factor Essential for Microtubule Assembly. PNAS, 72, 1858-1862.

[14]   Goedert, M., Wischik, C.M., Crowther, R.A., Walker, J.E. and Klug, A. (1988) Cloning and Sequencing of the cDNA Encoding a Core Protein of the Paired Helical Filament of Alzheimer Disease: Identification as the Microtubule-Associated Protein Tau. PNAS, 85, 4051-4055.

[15]   Reddy, P.H. and Beal, M.F. (2008) Amyloid Beta, Mitochondrial Dysfunction and Synaptic Damage: Implications for Cognitive Decline in Aging and Alzheimer’s Disease. Trends in Molecular Medicine, 14, 45-53.

[16]   Henderson, V.W., Paganini-Hill, A., Emanuel, C.K., Dunn, M.E. and Buckwalter, J.G. (1994) Estrogen Replacement Therapy in Older Women. Comparisons between Alzheimer’s Disease Cases and Nondemented Control Subjects. Archives of Neurology, 51, 896-900.

[17]   Henderson, V.W. (1997) Estrogen, Cognition, and a Woman’s Risk of Alzheimer’s Disease. The American Journal of Medicine, 103, 11S-18S.

[18]   Kelly, C.A., Harvey, R.J. and Cayton, H. (1997) Drug Treatments for Alzheimer’s Disease. British Medical Journal, 314, 693-694.

[19]   Corbett, A., Smith, J. and Ballard, C. (2012) New and Emerging Treatments for Alzheimer’s Disease. Expert Review of Neurotherapeutics, 12, 535-543.

[20]   Wilkerson, D. (2001) Drugs for Treatment of Alzheimer’s Disease. International Journal of Clinical Practice, 55, 129-134.

[21]   Max, W. (1999) Drug Treatments for Alzheimer’s Disease. CNS Drugs, 11, 363-372.

[22]   Doody, R.S. (2003) Current Treatments for Alzheimer’s Disease: Cholinesterase Inhibitors. The Journal of Clinical Psychiatry, 64, 11-17.

[23]   Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S. and Möbius, H.J. (2003) Memantine in Moderate-to-Severe Alzheimer’s Disease. New England Journal of Medicine, 348, 1333-1341.

[24]   Thompson, S., Herrmann, N., Rapoport, M.J. and Lanctôt, K.L. (2007) Efficacy and Safety of Antidepressants for Treatment of Depression in Alzheimer’s Disease: A Meta-Analysis. The Canadian Journal of Psychiatry, 52, 248-255.

[25]   Harada, A., Oguchi, K., Okabe, S., Kuno, J., Terada, S., Ohshima, T., et al. (1994) Altered Micro-tubule Organization in Small-Calibre Axons of Mice Lacking Tau Protein. Nature, 369, 488-491.

[26]   Howard, J. and Hyman, A.A. (2007) Microtubule Polymerases and Depolymerases. Current Opinion in Cell Biology, 19, 31-35.

[27]   Stoothoff, W.H. and Johnson, G.V.W. (2005) Tau Phosphorylation: Physiological and Pathological Consequences. Biochimicaet Biophysica Acta—Molecular Basis of Disease, 1739, 280-297.

[28]   Hernández, F., Gómezde Barreda, E., Fuster-Matanzo, A., Lucas, J.J. and Avila, J. (2010) GSK3: A Possible Link between Beta Amyloid Peptide and Tau Protein. Experimental Neurology, 223, 322-325.

[29]   Lin, M.T. and Beal, M.F. (2006) Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases. Nature, 443, 87-95.

[30]   Pike, C.J., Carroll, J.C., Rosario, E.R. and Barron, A.M. (2009) Protective Actions of Sex Steroid Hormones in Alzheimer’s Disease. Front Neuroendocrinol, 30, 239-258.

[31]   Kawas, C., Resnick, S., Morrison, A., Brookmeyer, R., Corrada, M., Zonderman, A., et al. (1997) A Prospective Study of Estrogen Replacement Therapy and the Risk of Developing Alzheimer’s Disease: The Baltimore Longitudinal Study of Aging. Neurology, 48, 1517-1521.

[32]   Paganini-Hill, A. and Henderson, V.W. (1996) Estrogen Replacement Therapy and Risk of Alzheimer’s Disease. Archives of Internal Medicine, 156, 2213-2217.

[33]   Tang, M.X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., et al. (1996) Effect of Oestrogen during Menopause on Risk and Age at Onset of Alzheimer’s Disease. The Lancet, 348, 429-432.

[34]   Waring, S.C., Rocca, W.A., Petersen, R.C., O’Brien, P.C., Tangalos, E.G. and Kokmen, E. (1999) Postmenopausal Estrogen Replacement Therapy and Risk of AD: A Population-Based Study. Neurology, 52, 965-970.

[35]   Zandi, P.P., Carlson, M.C., Plassman, B.L., Welsh-Bohmer, K.A., Mayer, L.S., Steffens, D.C., et al. (2002) Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women: The Cache County Study. JAMA, 288, 2123-2129.

[36]   Carlson, M.C., Zandi, P.P., Plassman, B.L., Tschanz, J.T., Welsh-Bohmer, K.A., Steffens, D.C., et al. (2001) Hormone Replacement Therapy and Reduced Cognitive Decline in Older Women: The Cache County Study. Neurology, 57, 2210-2216.

[37]   Rosario, E.R., Chang, L., Head, E.H., Stanczyk, F.Z. and Pike, C.J. (2011) Brain Levels of Sex Steroid Hormones in Men and Women during Normal Aging and in Alzheimer’s Disease. Neurobiology of Aging, 32, 604-613.

[38]   Hu, X.-Y., Qin, S., Lu, Y.-P., Ravid, R., Swaab, D.F. and Zhou, J.-N. (2003) Decreased Estrogen Receptor-Alpha Expression in Hippocampal Neurons in Relation to Hyperphosphorylated Tau in Alzheimer Patients. Acta Neuropathologica, 106, 213-220.

[39]   Alvarez-De-La-Rosa, M., Silva, I., Nilsen, J., Pérez, M.M., García-Segura, L.M., ávila, J., et al. (2005) Estradiol Prevents Neural Tau Hyperphosphorylation Characteristic of Alzheimer’s Disease. Annals of the New York Academy of Sciences, 1052, 210-224.

[40]   Galea, L.A.M., Frick, K.M., Hampson, E., Sohrabji, F. and Choleris, E. (2016) Why Estrogens Matter for Behavior and Brain Health. Neuroscience & Biobehavioral Reviews. (In Press)

[41]   Xu, Y., He, H., Li, C., Shi, Y., Wang, Q., Li, W., et al. (2011) Immunosuppressive Effect of Erogesterone on Dendritic Cells in Mice. Journal of Reproductive Immunology, 91, 17-23.

[42]   Zhao, L., Morgan, T.E., Mao, Z., Lin, S., Cadenas, E., Finch, C.E., et al. (2012) Continuous versus Cyclic Progesterone Exposure Differentially Regulates Hippocampal Gene Expression and Functional Profiles. PLoS ONE, 29, 7.

[43]   Haskell, S.G., Richardson, E.D. and Horwitz, R.I. (1997) The Effect of Estrogen Replacement Therapy on Cognitive Function in Women: A Critical Review of the Literature. Journal of Clinical Epidemiology, 50, 1249-1264.

[44]   Almeida, O.P., Lautenschlager, N.T., Vasikaran, S., Leedman, P., Gelavis, A. and Flicker, L. (2006) A 20-Week Randomized Controlled Trial of Estradiol Replacement Therapy for Women Aged 70 Years and Older: Effect on Mood, Cognition and Quality of Life. Neurobiology of Aging, 27, 141-149.

[45]   Barrett-Connor, E. and Kritz-Silverstein, D. (1993) Estrogen Replacement Therapy and Cognitive Function in Older Women. JAMA, 269, 2637-2641.

[46]   Brenner, D.E., Kukull, W.A., Stergachis, A., van Belle, G., Bowen, J.D., McCormick, W.C., et al. (1994) Postmenopausal Estrogen Replacement Therapy and the Risk of Alzheimer’s Disease: A Population-Based Case-Control Study. American Journal of Epidemiology, 140, 262-267.

[47]   Goebel, J.A., Birge, S.J., Price, S.C., Hanson, J.M. and Fishel, D.G. (1995) Estrogen Replacement Therapy and Postural Stability in the Elderly. American Journal of Otolaryngology, 16, 470-474.

[48]   Wiley, T.S. and Haraldsen, J.T. (2012) The Theory of Modulated Hormone Therapy for the Treatment of Breast Cancer in Pre- and Post-Menopausal Women. AIP Advances, 2, Article ID: 011206.

[49]   Wiley, T.S. and Haraldsen, J.T. (2014) The Effects of Steroid Hormone Exposure on Direct Gene Regulation. Medical Hypotheses, 83, 436-440.

[50]   Vande Wiele, R.L., Bogumil, J., Dyrenfurth, I., Ferin, M., Jewelewicz, R., Warren, M., et al. (1970) Mechanisms Regulating the Menstrual Cycle in Women. Recent Progress in Hormone Research, 126, 63-103.

[51]   Pozzi, S., Benedusi, V., Maggi, A. and Vegeto, E. (2006) Estrogen Action in Neuroprotection and Brain Inflammation. Annals of the New York Academy of Sciences, 1089, 302-323.

[52]   Vegeto, E., Benedusi, V. and Maggi, A. (2008) Estrogen Anti-Inflammatory Activity in Brain: A Therapeutic Opportunity for Menopause and Neurodegenerative Diseases. Frontiers in Neuroendocrinology, 29, 507-519.

[53]   Horwitz, K.B. and McGuire, W.L. (1978) Estrogen Control of Progesterone Receptor in Human Breast Cancer. The Journal of Biological Chemistry, 253, 2223-2228.

[54]   Chen, T.J. and Jow, G.M. (1989) Effects of Estrogen on Progesterone Receptor Synthesis during Endometrial Cell Culture. Journal of the Formosan Medical Association, 88, 456-461.

[55]   Segal, M. and Murphy, D. (2001) Estradiol Induces Formation of Dendritic Spines in Hippocampal Neurons: Functional Correlates. Hormones and Behavior, 40, 156-159.

[56]   Stuart, G., Spruston, N. and Häusser, M. (2016) Dendrites. Oxford University Press, Oxford, 642 p.

[57]   Kalaria, R.N., Cohen, D.L., Premkumar, D.R., Nag, S., LaManna, J.C. and Lust, W.D. (1998) Vascular Endothelial Growth Factor in Alzheimer’s Disease and Experimental Cerebral Ischemia. Brain Research. Molecular Brain Research, 62, 101-105.

[58]   Religa, P., Cao, R., Religa, D., Xue, Y., Bogdanovic, N., Westaway, D., et al. (2013) VEGF Significantly Restores Impaired Memory Behavior in Alzheimer’s Mice by Improvement of Vascular Survival. Scientific Reports, 3, 2053.